Author:
Foster Robert S.,Fowkes Adrian,Cayley Alex,Thresher Andrew,Werner Anne-Laure D.,Barber Chris G.,Kocks Grace,Tennant Rachael E.,Williams Richard V.,Kane Steven,Stalford Susanne A.
Abstract
AbstractThe use of in silico predictions for the assessment of bacterial mutagenicity under the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) M7 guideline is recommended when two complementary (quantitative) structure-activity relationship (Q)SAR models are used. Using two systems may increase the sensitivity and accuracy of predictions but also increases the need to review predictions, particularly in situations where results disagree. During the 4th ICH M7/QSAR Workshop held during the Joint Meeting of the 6th Asian Congress on Environmental Mutagens (ACEM) and the 48th Annual Meeting of the Japanese Environmental Mutagen Society (JEMS) 2019, speakers demonstrated their approaches to expert review using 20 compounds provided ahead of the workshop that were expected to yield ambiguous (Q)SAR results. Dr. Chris Barber presented a selection of the reviews carried out using Derek Nexus and Sarah Nexus provided by Lhasa Limited. On review of these compounds, common situations were recognised and are discussed in this paper along with standardised arguments that may be used for such scenarios in future.
Publisher
Springer Science and Business Media LLC
Subject
Environmental Science (miscellaneous),Genetics,Social Psychology
Reference23 articles.
1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7(R1). 2017. https://database.ich.org/sites/default/files/M7_R1_Guideline.pdf. Accessed 1 May 2020.
2. Sutter A, Amberg A, Boyer S, Brio A, Contrera JF, Custer LL, Dobo KL, Gervais V, Glowienke S, van Gompel J, Greene N, Muster W, Nicolette J, Reddy MV, Thybaud V, Vock E, White AT, Müller L. Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities. Regul Toxicol Pharmacol. 2013;67(1):39–52.
3. Kamber M, Flückiger-Isler S, Engelhardt G, Jaeckh R, Zeiger E. Comparison of the Ames II and traditional Ames test responses with respect to mutagenicity, strain specificities, need for metabolism and correlation with rodent carcinogenicity. Mutagenesis. 2009;24(4):359–66.
4. Hansen K, Mika S, Schroeter T, Sutter A, ter Laak A, Steger-Hartmann T, Heinrich N, Müller KR. Benchmark data set for in silico prediction of Ames mutagenicity. J Chem Inf Model. 2009;49(9):2077–81.
5. Barber C, Amberg A, Custer L, Dobo KL, Glowienke S, van Gompel J, Gutsell S, Harvey J, Honma M, Kenyon MO, Kruhlak N, Muster W, Stavitskaya L, Teasdale A, Vessey J, Wichard J. Establishing best practise in the application of expert review of mutagenicity under ICH M7. Regul Toxicol Pharmacol. 2015;73(1):367–77.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献